Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Drug Development: The role of innovation in drug development

Nature Biotechnology volume 15, pages 1318–1319 (1997)Cite this article

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium “The Genetic Basis of Human Disease”, October 2–3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.

  2. Lifton, R. Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium “The Genetic Basis of Human Disease”, October 2–3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.

  3. Weber, W. 1997. pp. 10–11 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.

    Google Scholar 

  4. Ohsako, S. and Deguchi, T. 1990. J. Biol. Chem. 265: 4630–4634.

    CAS  PubMed  Google Scholar 

  5. Weber, W. 1997. pp. 12–13 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.

    Google Scholar 

  6. Mossinghoff, G.J. 1995. Drug Info. J. 29: 1077–1090.

    Article  Google Scholar 

  7. Drews, J. and Ryser, S. 1997. Drug Discovery Today 2: 365–372.

    Article  Google Scholar 

  8. It is obvious that these constraints are entirely dependent on a set of financial assumptions relating to costs, sales and discount rates for R&D expenditures. If these assumptions are modified, if for instance the discount rates after launch are lowered from 14% to 8% or if only out of pocket expenses are taken into account and opportunity costs altogether neglected, the picture brightens considerably. Eventually, such changes may have to be made.

Download references

Author information

Authors and Affiliations

  1. president of global research and Stefan Ryser is chief of international research staff, Hoffmann-La Roche, CH-4002, Basel, Switzerland

    Jürgen Drews & Stefan Ryser

Authors
  1. Jürgen Drews
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Ryser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drews, J., Ryser, S. Drug Development: The role of innovation in drug development. Nat Biotechnol 15, 1318–1319 (1997). https://doi.org/10.1038/nbt1297-1318

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1297-1318

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing